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Recent genome-wide association (GWA) studies of lipids have been conducted in samples ascertained for other phenotypes,
particularly diabetes. Here we report the first GWA analysis of loci affecting total cholesterol (TC), low-density lipoprotein (LDL)
cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides sampled randomly from 16 population-based cohorts and
genotyped using mainly the Illumina HumanHap300-Duo platform. Our study included a total of 17,797–22,562 persons, aged
18–104 years and from geographic regions spanning from the Nordic countries to Southern Europe. We established 22 loci
associated with serum lipid levels at a genome-wide significance level (P o 5  108), including 16 loci that were identified by
previous GWA studies. The six newly identified loci in our cohort samples are ABCG5 (TC, P ¼ 1.5  1011; LDL, P ¼ 2.6 
1010), TMEM57 (TC, P ¼ 5.4  1010), CTCF-PRMT8 region (HDL, P ¼ 8.3  1016), DNAH11 (LDL, P ¼ 6.1  109), FADS3-
FADS2 (TC, P ¼ 1.5  1010; LDL, P ¼ 4.4  1013) and MADD-FOLH1 region (HDL, P ¼ 6  1011). For three loci, effect
sizes differed significantly by sex. Genetic risk scores based on lipid loci explain up to 4.8% of variation in lipids and were also
associated with increased intima media thickness (P ¼ 0.001) and coronary heart disease incidence (P ¼ 0.04). The genetic risk
score improves the screening of high-risk groups of dyslipidemia over classical risk factors.
Serum lipids are important determinants of cardiovascular disease and
are related to morbidity1–3. The high heritability of circulating lipid
levels is well established, and earlier studies of individuals with
extreme lipid values or families with mendelian forms of dyslipidemias
have exposed the involvement of numerous genes and respective
proteins in lipid metabolism1,4,5. Recent GWA studies mostly done
in study samples enriched with type 2 diabetes cases have implicated a
total of 19 loci controlling serum high-density lipoprotein cholesterol
(HDL), low-density lipoprotein cholesterol (LDL) and triglycerides
(TG)6–11. The loci include the genes encoding ABCA1, APOB,
CELSR2, CETP, DOCK7, GALNT2, GCKR, HMGCR, LDLR, LIPC,
LIPG, LPL, MLXIPL, NCAN, PCSK9 and TRIB1, and three genetic
regions with multiple associated genes including MVK-MMAB,
APOA5-APOA4-APOC3-APOA1 and APOE-APOC1-APOC4-APOC2.
Many of these have also been consistently associated with lipid levels
in candidate gene studies reported over the past 30 years12,13.
Currently identified common loci explain only a small fraction of
variation in the concentration of lipids within the population. In
contrast to rare variants with major effects such as those underlying
familial hypercholesterolemia, common variants improve the predic-
tion of cardiovascular disease only marginally in terms of the clinical
classification of patients14. As the genetic profiles studied are far from
complete, there is substantial room for further characterization of
genetic profiles influencing serum lipid levels.
GWA studies published so far have generally included subjects
ascertained for the presence or absence of a disease or trait component
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(particularly diabetes). Compared to population-based cohorts, such
ascertainment has the potential to generate bias with respect to both
the detection of associations and the estimation of their population-
level impact. Here we report the results of GWA analysis of 16
European studies (total number of persons 17,798–22,562, depending
on the lipid trait studied), representing population-based cohorts. We
combined these large cohorts to identify loci affecting serum levels of
HDL, LDL, TG as well as total cholesterol (TC) across different
European populations. We further examined whether the associated
lipid loci showed any sex-specific differences in effect size, as well as
their impact on cardiovascular morbidity in elderly cohorts.
RESULTS
Screening for new loci associated with lipid levels
Meta-analysis of GWA data from the ENGAGE cohort datasets
(Table 1) with respect to the levels of the four principal lipid
phenotypes (LDL, HDL, TC, TG) resulted in 162 signals with P
valueo5  108 (full list provided in Supplementary Table 1 online;
genome-wide association plots in Supplementary Fig. 1 online).
These 162 SNPs represent a total of 22 chromosomal loci associated
with serum lipid levels in the general population (Table 2). Of these,
16 regions have been identified in earlier GWA studies and 6 are newly
identified. As expected given the high correlations observed between
some of the lipid fractions (correlation up to 0.89 for LDL and TC in
the Northern Finnish Birth Cohort), several of the loci were associated
with multiple lipid measures.
For TC, we found 11 regions showing genome-wide significant
evidence for association. Of these, eight have previously been impli-
cated in GWA scans for LDL or TG (Table 2), and three (ABCG5
(rs6756629), FADS2-FADS3 (rs174570) and TMEM57 (rs10903129))
represent new loci. For LDL, out of eight associated loci, three
(ABCG5 (rs6756629), DNAH11 (rs12670798) and FADS2-FADS3
(rs174570)) were not known before. For HDL, eight regions showed
genome-wide significant results including two newly identified
regions, CTCF-PRMT7 (8 SNPs associated with P o 5  108) and
MADD-FOLH1 (9 SNPs associated). For TG, all seven regions show-
ing genome-wide significance in the current study were previously
implicated in the control of serum lipid levels (DOCK7, APOB, GCKR,
BAZ1B-BCL7B-TBL2-MLXIPL region, LPL-SLC18A1 region, BUD13-
APOA cluster (A1/A4/A5/C3), CEACAM16-TOMM40-APOE region).
Table 1 Table of cohorts, genotyping platforms and phenotype information of four lipid traits per cohort
TC N Mean (s.d.) TG N Mean (s.d.) LDL N Mean (s.d.) HDL N Mean (s.d.)
Study Genotyping platform Country Females Males Females Males Females Males Females Males
ATR, Australian twin registry Illumina 318K Australia 424 0 424 0 416 0 420 0
5.7 (1.1) 1.6 (1.0) 3.4 (1.0) 1.6 (0.4)
DK-TWIN, Danish twin registry Illumina 318K Denmark 169 0 140 0 138 0 140 0
5.4 (1.3) 1.2 (0.4) 3.1 (1.0) 1.6 (0.4)
ERF, Erasmus Ruchpen Family study Illumina 318K The Netherlands 510 319 510 319 509 315 510 319
5.6 (1.1) 5.4 (1.1) 1.3 (0.6) 1.6 (1.1) 3.7 (1.0) 3.7 (1.0) 1.4 (0.4) 1.1 (0.3)
FTC, Finnish twin cohort Illumina 318K Finland 138 0 41 0 138 0 138 0
5.4 (0.9) 1.2 (0.8) 3.5 (1.0) 1.6 (0.5)
KORA, Cooperative health research
in the Region of Augsburg
Affymetrix 500K Germany 830 813 830 813 830 813 830 813
5.8 (1.1) 5.6 (1.0) 1.7 (0.9) 2.2 (1.7) 3.4 (0.9) 3.3 (0.8) 1.7 (0.4) 1.3 (0.4)
MICROS, The genetic study of three
population microisolates in South Tyrol
Illumina 318K Italy 615 471 615 471 615 471 615 471
5.9 (1.2) 5.8 (1.2) 1.3 (0.7) 1.7 (1.3) 3.4 (1.1) 3.6 (1.1) 1.8 (0.4) 1.5 (0.3)
NFBC1966, Northern Finnish Birth
Cohort of 1966
Illumina 370K Finland 2,488 2,283 2,488 2,282 2,480 2,274 2,488 2,282
5.0 (1.0) 5.2 (1.0) 1.1 (0.6) 1.3 (0.8) 2.8 (0.8) 3.2 (0.9) 1.7 (0.4) 1.4 (0.3)
NSPHS, The Northern Swedish Population
Health Study
Illumina 318K Sweden 345 308 345 308 345 308 345 308
5.8 (1.3) 5.8 (1.3) 1.9 (1.1) 2.5 (1.9) 3.5 (1.1) 3.5 (1.1) 1.7 (0.4) 1.4 (0.3)
NTR, The Netherlands twin register Illumina 318K The Netherlands 251 0 250 0 250 0 269 0
4.9 (1.0) 1.1 (0.6) 2.8 (0.9) 1.5 (0.4)
NTRNESDA, The Netherlands Twin Register
and The Netherlands Study of Depression
and Anxiety
Affymetrix 600K The Netherlands 2,265
5.0 (1.1)
1,177
5.0 (1.0)
2,279
1.2 (0.7)
1,186
1.6 (1.0)
2,267
3.1 (1.0)
1,178
3.3 (0.9)
2,279
1.6 (0.4)
1,185
1.3 (0.4)
ORCADES, The Orkney Complex
Disease Study
Illumina 318K Scotland 384 330 384 331 384 330 384 331
5.9 (1.2) 5.6 (1.2) 1.3 (0.6) 1.4 (0.7) 3.5 (1.1) 3.6 (1.1) 1.8 (0.4) 1.5 (0.4)
Rotterdam Study Illumina 550K The Netherlands 3,475 2,399 1,430 929 1,390 912 3,460 2,389
6.8 (1.2) 6.3 (1.2) 1.6 (0.8) 1.5 (0.7) 3.9 (0.9) 3.6 (0.8) 1.4 (0.4) 1.2 (0.3)
STR, Swedish twin registry Illumina 318K Sweden 301 0 301 0 300 0 301 0
6.0 (1.1) 1.4 (0.8) 3.9 (1.0) 1.5 (0.4)
TwinUK, dizygotic twins of the
St. Thomas’ twin cohort
Illumina 318K UK 1,129 0 0 0 0 0 0 0
5.4 (1.2)
UK-TWIN, monozygotic twins of the
St. Thomas’ twin cohort
Illumina 318K UK 429 0 429 0 428 0 429 0
5.3 (1.2) 1.0 (0.8) 3.4 (1.0) 1.5 (0.4)
Vis study Illumina 318K Croatia 406 303 407 303 405 301 405 301
5.2 (1.0) 5.0 (1.0) 1.6 (0.8) 1.9 (1.1) 3.3 (1.0) 3.1 (0.9) 1.1 (0.1) 1.1 (0.2)
Subtotal 14,159 8,403 10,873 6,942 10,895 6,902 13,013 8,399
Total 22,562 17,815 17,797 21,412
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Within two of the newly identified loci, there was only one SNP
reaching genome-wide significance. However, for both regions, there
were multiple additional SNPs with suggestive association (not reach-
ing the level of 5  108, see Supplementary Fig. 2 online). When
comparing the effects of the 22 SNPs across the different populations,
we found that all SNPs showed consistent evidence for association
across European populations (Supplementary Fig. 3 online). As an
example of similarity of effects across the cohorts, Figure 1 shows the
forest plot of effects for rs7395662 (MADD-FOLH1) on high-density
lipoprotein. The estimated effect sizes are very similar across the
cohorts, particularly in the largest cohorts. The effects were also
similar for the two sexes.
Characterization of associated loci
We also evaluated the potential relevance for biological pathways
related to lipid metabolism by carrying out a genome-wide association
network analysis (GWANA) of associated SNPs. GWANA uses the
ranking of associated genes together with their biological pathway
information based on Gene Ontology to list pathways that are
enriched among the most highly associated genes. This is analogous
to the way pathway analyses of signals obtained in genome-wide
transcript data are analyzed15. We present GWANA results using data
for GWA-identified SNPs associated with TC (Fig. 2). The GWANA-
associated genes for TC, tagged by the best SNP per gene, showed
statistically significant clustering to highly relevant pathways shown in
green in Figure 2: two major pathway trees linked the TC-associated
genes to cholesterol and sterol metabolism, lipid transporters and even
nutrient response. We present the data of the GWANA analyses for
Table 2 SNPs achieving genome-wide significance
TC HDL LDL TG
SNP Chr. Position (Mb) Gene region Ref. allele CAa CAFb bc P value bc P value bc P value bc P value
rs10903129 1 25.51 TMEM57 A G 0.54 0.061 5.4E10 0.024 0.02 0.050 1.8E5 0.008 0.48
rs1167998 1 62.64 DOCK7 A C 0.32 –0.073 6.4E10 –0.033 3.8E3 –0.058 1.1E5 –0.091 2.0E12
rs10889353 1 62.83 DOCK7 A C 0.32 –0.079 3.7E12 –0.036 1.8E3 –0.060 7.9E6 –0.085 8.2E11
rs646776 1 109.53 CELSR2 A G 0.22 –0.128 8.5E22 0.037 6.2E3 –0.155 7.8E23 0.007 0.63
rs693 2 21.14 APOB A G 0.52 –0.096 8.7E23 0.054 1.3E7 –0.098 3.6E17 –0.043 1.4E4
rs6754295 2 21.12 APOB A C 0.25 –0.061 1.8E06 0.068 4.4E8 –0.074 1.6E7 –0.077 2.5E8
rs673548 2 21.15 APOB A G 0.76 0.052 7.4E05 –0.066 7.4E7 0.063 3.6E5 0.086 1.1E8
rs780094 2 27.65 GCKR A G 0.63 –0.023 0.02 0.016 0.12 0.002 0.85 –0.103 3.1E20
rs6756629 2 43.98 ABCG5 A G 0.92 0.145 1.5E11 –0.007 0.74 0.157 2.6E10 0.027 0.26
rs3846662 5 74.69 HMGCR A G 0.44 0.092 2.5E19 –0.006 0.57 0.079 1.5E11 0.025 0.03
rs12670798 7 21.38 DNAH11 A G 0.24 0.064 9.2E7 0.019 0.14 0.089 6.1E9 0.006 0.68
rs2240466 7 72.30 MLXIPL A G 0.87 0.004 0.80 –0.041 0.02 –0.015 0.44 0.137 1.1E12
rs2083637 8 19.91 LPL A G 0.26 –0.004 0.73 0.107 5.5E18 0.004 0.76 –0.107 1.0E14
rs10096633 8 19.88 LPL A G 0.88 –0.002 0.91 –0.141 6.1E16 –0.013 0.53 0.174 1.9E18
rs6987702 8 126.57 TRIB1 A G 0.29 0.073 3.3E9 0.010 0.44 0.068 2.9E6 0.058 5.2E5
rs3905000 9 104.74 ABCA1 A G 0.86 0.063 5.0E5 0.113 8.6E13 0.002 0.90 –0.023 0.20
rs7395662 11 48.48 MADD-FOLH1 A G 0.61 –0.005 0.63 –0.073 6.0E11 0.013 0.31 –0.008 0.54
rs174570 11 61.35 FADS2/3 A G 0.83 0.088 1.5E10 0.064 3.9E6 0.110 4.4E13 –0.063 2.9E5
rs12272004 11 116.11 APO(A1/A4/A5/C3) A C 0.93 –0.107 7.3E7 0.058 0.01 –0.085 9.9E4 –0.181 5.4E13
rs1532085 15 56.47 LIPC A G 0.59 –0.052 3.7E7 –0.130 9.7E36 0.006 0.60 –0.011 0.33
rs1532624 16 55.56 CETP A C 0.57 –0.028 0.01 –0.213 9.4E94 0.034 3.3E3 0.038 1.1E3
rs2271293 16 66.46 CTCF-PRMT8 A G 0.87 –0.023 0.14 –0.129 8.3E16 0.017 0.33 0.037 0.04
rs4939883 18 45.42 LIPG A G 0.83 0.073 2.4E7 0.103 1.6E11 0.034 0.06 0.028 0.11
rs2228671 19 11.07 LDLR A G 0.88 0.158 9.3E24 –0.010 0.54 0.136 4.2E14 0.010 0.59
rs2304130 19 19.65 NCAN A G 0.07 –0.153 2.0E15 –0.006 0.75 –0.116 1.5E7 –0.102 2.9E6
rs2075650 19 50.09 TOMM40-APOE A G 0.15 0.138 2.9E19 –0.059 1.9E4 0.160 9.3E19 0.065 2.4E4
rs157580 19 50.09 TOMM40-APOE A G 0.33 –0.090 5.1E17 0.055 3.6E7 –0.111 2.1E19 –0.069 1.2E8
rs439401 19 50.11 TOMM40-APOE A G 0.68 0.044 3.7E4 –0.037 2.7E3 0.037 1.1E2 0.086 1.8E9
In each region, the SNP with the lowest P value for one of the outcomes is shown. Newly identified regions and effects of known regions on new lipids are shaded with light gray. In
boldface are results with P value o5E–8. CA, coded allele (the allele for which effect was estimated); CAF, coded allele frequency; b, effect of the coded allele (in s.d.).
Vis Study females
ERF females
Rotterdam Study females
KORA females
MZ twins females
NFBC66 females
ORCADES females
NSPHS females
MICROS females
Summary females
Vis Study males
ERF males
Rotterdam Study males
KORA males
NFBC66 males
ORCADES males
NSPHS males
MICROS males
–
0.4
–
0.3
–
0.2
Effect, s.d.
–
0.1 0.10
Summary males
Summary
Figure 1 Effect of rs7395662 (MADD-FOLH1) on high-density lipoprotein
separately for different cohorts and sexes.
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other lipids in the Supplementary Table 2 and Supplementary
Figure 4 online.
When we tested for effect difference between males and
females among the associated loci, rs3846662 in HMGCR (effect in
males ¼ 0.049, effect in females ¼ 0.117; P ¼ 0.0013, Fig. 3)
and rs2304130 in NCAN (effect in males ¼ –0.234, effect in females
¼ –0.110; P ¼ 0.0019) showed significant differences in effect size
for TC. Similarly, rs2083637 in LPL showed different effects for
HDL (effect in males ¼ 0.149, effect in females ¼ 0.079;
P ¼ 0.0060), even after correction for multiple testing. Sex-specific
P-value plots for the four lipid traits are shown in Supplementary
Figure 5 online.
Genetic risk scores
Next, on the basis of loci discovered in our own and previous genome-
wide association findings, we constructed genetic risk scores (profiles)
for TC, HDL, LDL and TG in the three large cohorts (NFBC,
Rotterdam Study and MZ twins, n ¼ 12,361). The scores were
computed as weighted sums of the number of lipid level–increasing
(or decreasing for HDL) alleles carried by a person. To eliminate bias
arising from use of the same data both for defining the optimal
weights and for estimating the population effects, we based the
weighting on the estimated effect sizes of each allele across all the
study cohorts after excluding the study in which the risk score was
being applied.
For the TC risk score, we used the 11 SNPs listed in Table 2. For the
HDL risk score, we used the 8 SNPs showing genome-wide signifi-
cance in this study (Table 2) and rs2144300 tagging the previously
reported GALNT2 locus, rs2338104 tagging the KCTD10-MVK-
MMAB region7, and rs12272004 tagging the APOA1/A4/A5/C3
region6. For the LDL risk score, we used eight SNPs showing
genome-wide significance in this study (Table 2) plus rs11206510 in
PCSK9 and rs16996148 in NCAN-CILP2 (ref. 7) loci. For the TG
score, in addition to the seven SNPs shown in Table 2, we used three
SNPs from TRIB1 (rs17321515), NCAN-CILP2 (rs16996148) and
LIPC (rs4775041)7. In the three cohorts, the genetic risk profile
explained 3.9% of the total variance in sex- and age-adjusted TC.
Similarly, genetic risk profiles explained 4.8%, 3.4% and 3.0% of age-
adjusted variances in HDL, LDL and TG, respectively. In Table 3
and Supplementary Figure 6 online, we show these variance decom-
positions separately for both sexes in the three cohorts (total n ¼
12,361). Because the three cohorts differ appreciably in terms of age
distribution, results are reported separately for NFBC (all participants
aged 31), MZ twins (mean age 50) and the Rotterdam Study (mean
age 69). The genetic risk profiles seem to account for similar propor-
tions of variance regardless of age patterns except for LDL, where the
proportion of variance explained by associated genes seems to drop in
the older cohorts. The lipid variance explained by the genetic risk
score approaches that explained by the body mass index (BMI), a
traditional risk factor for cholesterol.
Lipid values are widely applied predictors for cardiovascular dis-
eases in the clinical setting. One of our older cohorts, the Rotterdam
Study (all subjects over 55 years of age) had follow-up for clinical
events. In this cohort, we could test for association between the genetic
risk profiles and end-points of clinical relevance, including intima
media thickness (IMT) and incident coronary heart disease (CHD).
Of the five risk profiles (TC, HDL, LDL, TG specific and a ‘combined
profile’ including all associated SNPs for the four traits), the TC
profile and the combined profile were most strongly associated with
relevant clinical outcomes. The TC risk profile was significantly
(P o 0.001) associated with clinically defined hypercholesterolemia
(serum cholesterol over 6.5 mmol/l), suggesting that the joint testing
of the loci will be clinically relevant to ascertain high risk groups. TC
risk scores improved the prediction of hypercholesterolemia beyond
that achieved with age, sex and body mass index (AUC (area under the
receiver-operating-characteristic curve) increase from 0.63 (95%
CI ¼ 0.61–0.64) to 0.66 (95% CI ¼ 0.65–0.67)). The TC genetic
risk score was significantly associated with IMT (P ¼ 0.001).
This association was still significant (P ¼ 0.043) after adjust-
ment for circulating levels of TC. In line with these findings and
those of others14, neither the TC risk scores nor the other four genetic
risk scores improved the prediction of incident CHD. The TC
genetic risk score was also associated with risk of incident CHD
(P ¼ 0.042), but the association did not remain significant after
addition of circulating levels of TC into the model, implying that TC
levels are in the causal pathway in between the genetic variants and
the disease.
Lipid
transport
Regulation of
protein transport
Regulation of
hydrolase activity
Humoral
immune
response
Response to
nutrients
Cholesterol
metabolic
process
Response
to nutrient
levels
Steroid
metabolic
process
Response to
extracellular
stimulus
TC
Sterol
metabolic
process
Figure 2 Pathways containing an enrichment of the most strongly associated
genes with total cholesterol (green circles) and their connections.
Vis Study females
ERF females
Rotterdam Study females
MZ twins females
NFBC66 females
NTRNESDA females
ORCADES females
NSPHS females
TwinUK females
MICROS females
Summary females
Vis Study males
ERF males
Rotterdam Study males
NFBC66 males
NTRNESDA males
ORCADES males
NSPHS males
MICROS males
Effect, s.d.
–
0.1 0 0.1 0.2 0.40.3
Summary males
Summary
Figure 3 Effect of rs3846662 (HMGCR) on total cholesterol separately for
different cohorts showing different effects for the two sexes.
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DISCUSSION
We aimed to identify loci involved in the regulation of circulating lipid
levels. Screening for increased circulating lipid levels and early treat-
ment with statins is one of the key strategies in the prevention of
cardiovascular risk in clinical practice, and dietary change is the
primary prevention strategy at the population level. Potential new
lipid-associated loci could contribute to these prevention strategies.
We used GWA data from 16 cohorts, including three large cohorts
each over 3500 samples (NFBC, Rotterdam Study and NTRNESDA)
and 13 smaller cohorts from across Europe. We have identified six new
risk loci and confirmed 16 regions previously associated with lipid
metabolism in earlier GWA studies6–8,14. All newly identified regions
showed robust effects across the study cohorts, which had different age
distributions, geographic origins and lifestyle patterns (Supplemen-
tary Fig. 3). It is of interest that 16 out of 22 loci had been previously
identified in case-control studies, most with samples enriched by type
2 diabetes cases, suggesting that effects seen in diabetic individuals are
independent of the disease. It remains to be determined whether
effects of the new loci we identified are also observed in individuals
with diabetes.
We have compared the effect estimates obtained in our meta-
analysis and those reported in Kathiresan et al., which is a Swedish
population-based study14. From 24 SNPs presented in Kathiresan
et al., all but two (rs11591147 and rs599838) were typed in at least
one population used in the present study. For most loci, similar
estimates of effect sizes were obtained from our population-based
cohorts and the cohort used by Kathiresan et al. However, the effect of
rs6511720[T] in LDLR on LDL was estimated as –0.26 ± 0.02 s.d. by
Kathiresan et al. and –0.15 ± 0.03 s.d. in our analysis; this effect
difference is significant (nominal P ¼ 0.002) and remained so after
multiple-testing correction for the 22 SNPs compared.
Our study samples were compiled from the population cohorts of
the ENGAGE project, which aims to provide an infrastructure to
combine large study samples and datasets across populations of
European origin. Out of the 22 associated loci, a total of 11 were
associated with TC, including three new ones in addition to 8 loci
earlier associated with the level of LDL. Out of three new TC-
associated loci, ABCG5 (rs6756629) and FADS2-FADS3 were asso-
ciated with both TC and LDL, whereas TMEM57 only showed
genome-wide significant association with TC and a much weaker
association with LDL (Table 2).
Among the six newly identified lipid-associated loci, two include
genes encoding proteins known to be involved in lipid metabolism
based on either the data from experimental animal studies or mono-
genic human diseases. One of them is part of the FADS2-FADS3 (fatty
acid desaturase 2 and 3) gene cluster, a gene family encoding proteins
that regulate desaturation of fatty acids through the introduction of
double bonds between defined carbons of the fatty acyl chain. The
second obvious functionally relevant gene is ABCG5 (ATP-binding
cassette transporter family member 5). The corresponding protein
functions as a half-transporter, dimerizing with ABCG8 to form a
functional complex necessary for efflux of dietary cholesterol and
noncholesterol sterols from the intestine and liver. Mutations
in ABCG5 are known to cause the rare monogenic disorder
sitosterolemia, characterized by abnormal absorption of cholesterol
and other sterols (MIM210250), and variants of this gene have been
shown to regulate blood cholesterol levels (and risk of gallstones)
in humans16.
For the other four newly identified loci, the role in lipid metabolism
is less obvious. The first, here assigned as MADD-FOLH1 locus of
chromosome 11p, represents a gene desert close to the centromere
with no known gene on the 500-kb flanking region, and the two genes
flanking the locus, MADD and FOLH1, have not been implicated in
lipid metabolism. However, NR1H3, or LXRA, an orphan member of
the nuclear receptor superfamily, is located just 0.5 kb telomeric of
MADD and an associated SNP in this gene was reported in the NFBC
cohort17. The liver X receptors (LXRs) are established mediators of
lipid-inducible gene expression. At the second locus, the CTCF-
PRMT8 gene encodes a transcriptional regulator potentially involved
in hormone dependent gene silencing. At the third, the DNAH11 gene
encodes a member of the dynein heavy chain family known to be
involved in the movements of cellular cilia. Finally, TMEM57 encodes
a membrane protein with poorly characterized function. Further
studies are needed to examine the potential role of these or neighbor-
ing genes in lipid metabolism.
None of the published GWA studies have addressed the potential
sex-based difference in genetic risk profiles for lipids. Here we found
significantly different sex-specific effects for some genes, as expected
from epidemiological and clinical data18. Lipid values for males and
females are known to differ, as does the prevalence of cardiovascular
diseases19. The two loci showing the strongest evidence for sex-based
differences in effect size are those containing HMGCR (3-hydroxy-3-
methylglutaryl-Coenzyme A reductase (HMGCoA) and NCAN (neu-
rocan). HMGCR is the rate-limiting enzyme for cholesterol synthesis
and the drug target for statins20, commonly used for treating high
LDL values21. Variants in HMGCR have recently been associated with
reduced efficacy of pravastatin therapy22. Previous GWA studies have
provided compelling evidence that common intronic variants of this
gene are associated with LDL cholesterol, with 0.1 mmol/l difference
between two homozygote classes7. The second gene with a potential
sex-specific effect, NCAN, encodes a chondroitin sulfate proteoglycan
thought to be involved in the modulation of cell adhesion and
migration. The locus flanking the NCAN gene has previously been
associated with both LDL and TG8.
Just as for sex-associated differences, we might have expected to see
differences in genetic profiles among European populations with large
differences in average levels of serum lipids. Notably, the direction of
the change in lipid level as well as the effect of the associated variants
Table 3 Proportion of variance (%) explained by genes and BMI in the Rotterdam Study, MZ twin cohorts and NFBC by sex
TC HDL LDL TG
Cohort Sex Genes (%) BMI (%) Genes (%) BMI (%) Genes (%) BMI (%) Genes (%) BMI (%)
Rotterdam Study Female 4.0 1.4 4.3 3.6 3.6 0.07 4.2 5.1
Rotterdam Study Male 3.5 0.5 4.5 2.9 1.0 0.0009 3.3 4.5
Monozygotic twins Female 3.2 0.2 4.3 10.0 4.2 1.1 2.6 6.8
Northern Finnish birth cohort Female 4.8 2.5 4.3 8.7 5.3 5.6 2.1 8.8
Northern Finnish birth cohort Male 3.6 4.1 6.6 9.6 3.9 4.2 2.6 13.9
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was for most of 22 loci quite similar across the various European
populations. This could indicate that the contribution of lifestyle and
environmental variation may have limited impact on observed
between-population differences in lipid levels. More likely, perhaps
our study design selected for detection of signals that show consistent
effects across populations, and was biased against the identification of
loci that have substantial heterogeneity of effect size.
Lipid-associated loci described in this study were not significantly
associated with BMI in our cohorts, although obesity itself is corre-
lated with lipid levels23. The proportion of variance explained by all 22
loci for lipid levels in our general population samples was comparable
to that explained by BMI, although the percentage of variance
explained is still small.
To evaluate the clinical relevance of genetic ‘risk profiles’, we carried
out a prospective analysis of the oldest cohort data. The genetic risk
scores were predictive of dyslipidemia, improving discriminative
accuracy, measured by AUC, from 63% (age, sex and BMI alone) to
66%. This improvement due to the genetic score is bigger than in
most recently reported AUCs24 and suggests that genetic profiles may
be useful for the early detection and treatment of dyslipidemias and
related cardiovascular risk, thus enabling early preventive strategies. In
line with earlier data14, we saw an improvement in CHD risk
classification when adding the genetic profile to the ‘traditional’
clinical risk factors of lipid values, age, BMI and sex (such as
Framingham25 or QRISK scores26). One noteworthy observation
from our study is that the genetic risk profile identified for TC
seems to represent the most informative score when relating the
data to clinically relevant outcomes such as clinical hypercholester-
olemia, intima media thickness and coronary heart disease. Until now,
none of the GWA studies had targeted the TC phenotype (which
represents a composite of LDL, HDL and VLDL cholesterol) for
examination. Our findings suggest that the genetic score for TC is
the most powerful option for predicting atherosclerosis and CHD.
We report here the first GWA study for serum lipid levels conducted
in population cohorts, not ascertained for any specific disease. We
identified a total of 22 loci, including six new ones. Some of these loci
show different impact for males and females. The genetic risk scores
constructed from the associated genes for each lipid trait provided
explanatory value comparable to that of BMI. These genetic profiles
seem to improve the identification of those at high risk of dyslipide-
mia but do not yet improve the prediction of atherosclerosis and
CHD over classical risk factors.
METHODS
Study cohorts. We provide basic features of the population samples as well as
the distribution of lipid values within individual cohorts and in the total study
sample in Table 1. Informed consent was obtained from all study subjects and
study protocols were approved by an appropriate local committee.
Twin sample. The Danish, Dutch, Finnish, Italian, Norwegian and Swedish
national twin cohorts, together with St. Thomas’ twin cohort in Great Britain
and an Australian twin cohort, form the basis of the GenomEUtwin project, a
collection of over 300,000 twins27. From these cohorts, we selected female
monozygotic pairs aged 20–80 years with blood lipid measurements available
on both members. The sample consisted of pairs from Australia (459 pairs),
Denmark (173 pairs), Finland (152 pairs), The Netherlands (331 pairs), Sweden
(301 pairs) and the UK (462 monozygotic (MZ) pairs and 3,000 dizygotic (DZ)
pairs). DNA samples from one member of each monozygotic twin pair were
used for genotyping (twin cohort details; S.R. et al., unpublished data).
Northern Finnish Birth Cohort of 1966 (NFBC1966). Mothers expected to
give birth in the two northern provinces of Oulu and Lapland in 1966 were
enrolled in NFBC1966 (n ¼ 12,058 live births)28. At the 31-year clinical
examination, participants provided fasting blood samples for evaluation of
the metabolic measures that are the focus of the current study (n ¼ 5654), and
DNA was also extracted from the blood samples provided at this time. All DNA
samples for the Illumina Infinium 370cnvDuo array were prepared for
genotyping by the Broad Institute Biological Sample Repository (BSP) as a
part of STAMPEED consortium funded by the US National Heart, Lung, and
Blood Institute.
Rotterdam Study. The Rotterdam Study29 is a prospective cohort study that
started in 1990 in Ommoord, a suburb of Rotterdam, among 10,994 men and
women aged 55 and over. The main objective of the Rotterdam Study is to
investigate the prevalence and incidence and risk factors for cardiovascular,
neurological, locomotor and ophthalmologic diseases in the elderly. Baseline
measurements were obtained between 1990 and 1993. All participants were
subsequently examined in follow-up examination rounds every 2–3 years. For
this study, we used 6,000 participants for whom GWA data were available;
nonfasting total cholesterol and HDL was available for most study participants;
fasting TC, HDL and TG were available for 2,300 participants of Rotterdam
Study 3 (1997–1999). LDL was estimated using the Friedewald formula, eLDL¼
TC – HDL – 0.456 TG (mmol/l), using nonfasting samples only30. Nonfasting
TC and HDL and fasting TG and estimated LDL were used in this study.
EUROSPAN. The European Special Populations Network (EUROSPAN)
consortium consists of five population samples: (i) the Erasmus Ruchpen
Family (ERF) study conducted in The Netherlands, (ii) the MICROS study
conducted in Italy, (iii) the Northern Swedish Population (NSP), (iv) the
Orkney Complex Disease Study (ORCADES; Scotland) and (v) the Vis study
conducted in Croatia. All EUROSPAN cohorts were genotyped using Illumina
317K platform. A brief description of each population is given below.
The ERF study31 is a family-based study that includes over 3,000 participants
descending from 22 couples living in the Rucphen region in the 19th century.
Participants were clinically examined in person and provided fasting blood
samples for metabolic measurements and DNA extraction. The 800 participants
included in this study consisted of the first series of participants for whom
GWA data were available.
The MICROS study32 is part of the genomic healthcare program ‘GenNova’.
The MICROS was an extensive survey carried out during 2001–2003 in three
villages of the Val Venosta on the populations of Stelvio, Vallelunga and
Martello. Information on the health status of participants was collected through
a standardized questionnaire, and lipids were measured with standard blood
analyses. The 1,100 participants included in this study are those for whom both
phenotypic and GWA data were available.
The Northern Swedish Population Health Study (NSPHS) represents a
family-based prospective population study located in the parish of Karesuando,
in the subartic region of the County of Norrbotten. This parish has about 1,500
inhabitants, 740 of whom participated in the study. Historic population
accounts show that there has been little immigration or other dramatic
population change in this area during the last 200 years. The study includes
a comprehensive health investigation and collection of data on family structure,
lifestyle, diet, medical history and samples for clinical chemistry, RNA and
DNA analyses.
The Orkney Complex Disease Study (ORCADES) is an ongoing family-
based genetic epidemiology collection in the isolated Scottish archipelago of
Orkney. Genetic diversity is decreased compared to mainland Scottish samples,
consistent with the high extent of endogamy historically. Samples from
800 individuals from a subgroup of ten islands with age 18–100 years were
included in the present study.
The Vis study33 includes unselected Croatians, aged 18–93 years, who were
recruited during 2003 and 2004 from the villages of Vis and Komiza on the
Dalmatian island of Vis. Biochemical and physiological measurements were
done, detailed genealogies reconstructed, questionnaire of lifestyle and envir-
onmental exposures collected, and blood samples and lymphocytes extracted
and stored for further analyses. The 800 participants included in this study were
these who had both GWA and phenotypic data available.
NTR/NESDA. The NTR/NESDA samples include Dutch twin families from
the Netherlands Twin Register (NTR) and participants from the Netherlands
Study of Depression and Anxiety (NESDA)34. We selected 1,862 unrelated
participants with a depression or anxiety related diagnosis (MDD) and 1,857
unrelated controls at low liability for MDD for genome-wide genotyping with
support of the US Foundation for the National Institutes of Health Genetic
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Association Information Network (FNIH/GAIN). This is the only cohort with
some trait-specific ascertainment. Baseline characteristics of NTR and NESDA
participants have been previously described34. The average age of participants
was 43.6 years (65% women) and lipids were measured from fasting blood
samples. Genotyping was conducted by Perlegen Sciences.
Cooperative health research in the Region of Augsburg (KORA). The KORA
research project has evolved from the WHO MONICA study (Monitoring of
Trends and Determinants of Cardiovascular Disease). The KORA genome-wide
association study was done using samples from the KORA S3 survey, which is a
population-based sample from the general population living in the region of
Augsburg, Southern Germany35. Standardized examinations of 4,856 partici-
pants, aged 25 to 74 years, were done during 1994–1995 (ref. 35) with follow-
up examination of 3,006 participants in 2004–2005 (KORA F3). For the
genome-wide study we selected 1,644 subjects from KORA S3/F3.
Genotyping. Most of the study cohorts used Infinium II assay36 on the
HumanHap300-Duo Genotyping BeadChips (Illumina), although other chips,
including Affymetrix, were used for 15% of the samples. Full details are given in
Table 1. For the purpose of future meta-analysis, quality control was restricted
to individual-level checks, done in each study group separately. The overall
recommendation was to exclude individuals with low call rate, excess hetero-
zygosity, mismatch between reported and genetically determined sex, SNP calls
indicating simultaneous presence of two X and a Y chromosomes, or non-
European ancestry. We used the identity-by-descent (IBD) analysis option of
PLINK37 or the genomic kinship option of GenABEL38 to determine related-
ness among our sample subjects, and to identify sample duplications. In
population-based samples, this information was also used to identify sample
contamination (subjects who seemed to be related to nearly everyone in the
sample) and unexpected close relatives. If the sample duplication issue could
not be resolved by external means, both samples were excluded. People of non-
European ancestry were identified using principal components analysis of the
IBD or genomic kinship matrices39 and excluded from analysis. Full details of
the ENGAGE quality control and analysis report format recommendations can
be found at the ENGAGE website (see URLs section below).
Before meta-analysis, individual study SNPs were filtered to satisfy call rate
490%, Hardy-Weinberg equilibrium (HWE) test P value 4108 and minor
allele frequency (MAF) 40.5%.
Statistical analysis. Within each cohort, blood lipid measurements were
stratified by sex; in each stratum, outcomes were adjusted for age using a
linear regression model and the residuals were standardized and used as
outcome measures in the subsequent sex-specific association testing. In
monozygotic twins, the mean of the two lipid measurements in a pair was
used as the raw phenotype, thereby halving error variance and increasing power
for association analysis (S.R., unpublished data). Triglycerides were log-trans-
formed before regressing in all cohorts. For genotype–lipid association analyses,
we assumed an additive mode of inheritance. Association analyses were
conducted using GenABEL38 and PLINK37.
The results from all cohorts were combined into a fixed-effects meta-analysis
with reciprocal weighting on the square of standard errors of the effect size
estimates, using the MetABEL package. Genomic control correction40 was
applied to correct standard errors before pooling. All population-based cohorts
showed low overdispersion (l o 1.05), whereas family-based cohorts (ERF,
NSP, MICROS, ORCADES, Vis), as expected, showed larger values of l. In the
pooled data, l was 1.02 for TC, LDL and HDL, and 1.01 for TG.
The difference between estimated effects in males and females was tested
using the t-test. Population heterogeneity of effects was assessed using
Cochran’s Q test.
The ranking of the SNP associations for each trait was the input for the
GWANA pathway analysis. These SNPs were mapped to the human genes using
cross-references in the Ensemble database and the genes were queried for their
Gene Ontology annotations. The topology of the Gene Ontology tree was fully
used by enumerating all available routes toward the root of the Gene Ontology
tree and adding all available vertexes as Gene Ontology annotations of the given
gene. For detecting the Gene Ontology gene groups (‘pathways’), a cumulative
score based on how extreme the observed combination of associated genes in a
given pathway is is compared to the all associated genes and their pathways.
The more genes a pathway had among all top-ranked genes, the smaller the
cumulative score. The observed cumulative scores were further compared with
permuted values, where the original SNP-based P-value ranks were permuted
and the cumulative scores were recalculated for each permutation round. The
top pathways and their permuted scores are reported in the Supplementary
Table 2 and Supplementary Figure 4.
In the Rotterdam Study, where we tested effects of risk scores on lipid levels,
intima media thickness and coronary heart disease, B2.5 million SNPs were
imputed using release 22 HapMap CEU population as reference. The imputa-
tions were done using MACH software41. The quality of imputations was
checked by comparing imputed and actual genotypes at 78,844 SNPs not
present on the Illumina 550K array for 437 individuals for whom these SNPs
were directly typed using the Affymetrix 500K chip. Using the ‘best guess’
genotype for imputed SNPs, we calculated a concordance rate of 99% for SNPs
with R2 (ratio of the variance of imputed genotypes to the binomial variance)
quality measure greater than 0.9; concordance was still high (94%) when R2
was between 0.5 and 0.9. All SNPs analyzed for association with lipid levels,
except two, had R2 4 0.96; two exceptions were rs4775041 (R2 ¼ 0.83) and
rs439401 (R2 ¼ 0.65).
Genetic scores were used to assess the proportion of variance explained by
lipid genes and their impact onto clinically relevant outcomes (intima media
thickness, coronary heart disease and dyslipidemia). We used a genetic score
defined as a weighted sum of the risk alleles, with weights proportional to the
effect estimates obtained in meta-analysis. Risk alleles were defined as those
increasing levels of TC, LDL or TG, or decreasing the levels of HDL. Five
genetic scores (TC, LDL, HDL, TG and total) were analyzed.
To avoid bias in estimation of the proportion of variance explained by the
risk score in a particular cohort, we re-estimated the weights of the risk score
(allelic effects) by meta-analysis of all cohorts except the one where the
proportion was computed afterwards. For example, when estimating the
proportion of variance explained in the Rotterdam Study, we used allelic effect
estimates from meta-analysis of all studies but the Rotterdam Study, and so on.
We analyzed association of the allele scores with incident CHD and
dyslipidemia in the Rotterdam study using SPSS 15.0. For analysis of incident
CHD, we used the Cox proportional hazards model to estimate hazard ratios
and the significance of their deviation from unity. Association between the
genetic risk score and dyslipidemia at baseline was assessed using logistic
regression. Four prediction models were investigated: (i) age and sex; (ii) age,
sex and allele score; (iii) age, sex and clinical variables; and (iv) age, sex, clinical
variables and allele score. The contribution of the allele scores to the prediction
of CHD and dyslipidemia was investigated by comparing the area under the
receiver-operating-characteristic curves (AUC) of the prediction models. AUC
estimates were obtained using the ROC plot function of SPSS, on the basis of
the linear predictors obtained from the Cox proportional hazards analyses and
the predicted probabilities from the logistic regression analyses. Dyslipidemia
was defined as total cholesterol levels equal or higher than 6.5 mmol/l.
The proportion of explained variance was assessed in the Rotterdam Study,
NFBC66 and MZ twin cohorts. Because some of these cohorts were matched
for sex or age, we stratified for sex and used residuals from linear regression of
the lipid levels on age to estimate the comparative effect of genetic score and
body mass index (BMI). The proportion of variance attributable to each of the
two predictors was assessed by fitting an ANOVA analysis of the linear
regression model (‘‘lm’’ and ‘‘anova’’ functions of R).
URLs. ENGAGE consortium, http://www.euengage.org/; PLINK software for
GWA analysis, http://pngu.mgh.harvard.edu/~purcell/plink/; GenABEL soft-
ware for GWA analysis and MetABEL for GWA meta-analysis, http://mga.
bionet.nsc.ru/~yurii/ABEL/; MACH software for SNP imputations, http://
www.sph.umich.edu/csg/abecasis/MaCH/index.html; R language and environ-
ment: http://www.r-project.org/.
Note: Supplementary information is available on the Nature Genetics website.
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